Zymeworks share price today

Zymeworks Inc.'s share price was $30.94 at the close on 4 November 2026. It has been rising for 3 weeks. That is 22.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $16 and $31, and at that close it was at the high of that range.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Zymeworks Inc. is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row.

Over the last 9.5 years the share price moved +137% while the S&P 500 moved +220%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Zymeworks Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Zymeworks is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Zymeworks Inc. posted a net loss of ₹0.05 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.1 B. That loss is 980.8% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹0.0 B. 11 of the last 12 reported quarters were loss-making.

Jun 2026 profit was ₹0.0 B, −2,043.0% on a year earlier.

Read this profit with care: at ₹0.0 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −919.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Zymeworks Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, −90.6% on the same quarter a year earlier. Over 4 years it has grown 41.2% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.0 B.

Revenue is everything the company billed its customers in the period.

FY25 revenue was ₹0.1 B, +38.9% on the year before.

Recent pace: the last four quarters grew −50.3% on average, against 41.2% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −69.8%, against −23.1% a year over the last 8 quarters (rolling over).

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Zymeworks Inc.'s operating margin was −919.0% in the Jun 2026 quarter, 917.6 percentage points lower than the same quarter a year ago. Across 5 years it has been between −806.9% and 31.6%. The latest quarter is below every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed −917.6 percentage points on the year while gross margin changed −527.0 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Zymeworks Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.0 B of cash, against −₹0.1 B of profit. After ₹0.0 B of spending on assets, free cash was ₹0.0 B: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Zymeworks Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Spending on assets: ₹0.0 B over the last 3 years.

In short: almost nothing is being spent on new assets, so the cash goes on running the business.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Zymeworks Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Zymeworks Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Zymeworks Inc. earned a ROE of −30% in FY25. That is up from a low of −85% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −2,044%, a number that says nothing useful about the business. It comes from a −76.6% net margin and 0.31× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a −76.6% net margin × 0.31× asset turnover × 1.29× leverage (assets divided by equity) ≈ −30.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed.

Zymeworks Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.1 B as of Jun 2026, so its debt is 0.20× its equity, which is very little. Year by year, that ratio went from 0.13 in FY21 to 0.07 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

8.5% of Zymeworks Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 5.1 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Zymeworks Inc., the Z-score is −1.58. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of −1.58 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Zymeworks Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Zymeworks is the 74th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Immunome, Inc., Aurinia Pharmaceuticals Inc. and Septerna, Inc. Just below it: Lakefront Biotherapeutics NV, Fortrea Holdings Inc. and Sarepta Therapeutics, Inc.

Biotechnology companies close in size

71. Immunome, Inc. $2.3 billion
72. Aurinia Pharmaceuticals Inc. $2.3 billion
73. Septerna, Inc. $2.2 billion
74. Zymeworks Inc. $2.2 billion
75. Lakefront Biotherapeutics NV $2.1 billion
76. Fortrea Holdings Inc. $2 billion
77. Sarepta Therapeutics, Inc. $2 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

1914. Veeco Instruments Inc. $2.2 billion · Semiconductor Equipment & Materials
1915. Perrigo Company plc $2.2 billion · Drug Manufacturers - Specialty & Generic
1916. Zymeworks Inc. $2.2 billion
1917. The Bank of N.T. Butterfield & Son Limited $2.2 billion · Banks - Diversified
1918. Capri Holdings Limited $2.2 billion · Luxury Goods

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.